• Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer 
  • Divarasib showed clinically meaningful improvements in progression-free survival compared to approved  KRAS G12C inhibitors; no new safety signals were observed
  • Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population
  • Data will be submitted to health authorities and presented at an upcoming medical meeting